Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Chronological age predicts suboptimal multiple myeloma treatment independent of frailty and socioenvironmental factors: A retrospective multi-center cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

BBBritney BellNDNhan DoCDClark DuMontier

Discussion

Loading...

Member takes

Overview

Retrospective cohort analysis finds chronological age significantly impacts optimal therapy receipt in multiple myeloma, suggesting a need for integrated frailty assessments.

Key Points

  • To evaluate how chronological age and frailty influence the receipt of optimal treatment for multiple myeloma.
  • Retrospective analysis of patients with newly diagnosed multiple myeloma at VA and MedStar systems.
  • Evaluated associations of chronological age and frailty using the Veterans Affairs Frailty Index.
  • Utilized multivariable logistic regressions to assess treatment receipt, adjusting for several demographic and clinical factors.
  • 71.9% of the VA cohort and 75.7% of the MedStar cohort received optimal therapy.
  • Every year of increasing age associated with lower odds of receiving optimal treatment in both cohorts.
  • Frail patients in the VA cohort were less likely to receive optimal treatment compared to robust patients, whereas no difference was found in the MedStar cohort.

Cite This Study

Bell et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7f4https://doi.org/10.1182/blood-2025-2808
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Age-centric insights: A single-center analysis of clinical presentation, treatment approaches, and outcomes in multiple myeloma patients across different age groups.2026
  2. 2Abstract 848: Influence of young age at diagnosis on the clinical presentation of disease and survival among patients with multiple myeloma2024
  3. 3Advances in the application of frailty scoring in the diagnosis and management of elderly patients with multiple myeloma (Review)2026
  4. 4Improved survival in patients with multiple myeloma over time: A retrospective single-center study focusing on patients aged 80 years and above2025
  5. 5Outcomes and associated factors after melphalan 140 mg/m² autologous hematopoietic cell transplantation for multiple myeloma in patients over 70 years of age2025